Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,864 Million (Mid Cap)
14.00
NA
3.58%
0.03
19.30%
2.00
Revenue and Profits:
Net Sales:
866 Million
(Quarterly Results - Jun 2026)
Net Profit:
177 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.27%
0%
4.27%
6 Months
-15.96%
0%
-15.96%
1 Year
-24.34%
0%
-24.34%
2 Years
14.4%
0%
14.4%
3 Years
30.52%
0%
30.52%
4 Years
58.56%
0%
58.56%
5 Years
55.44%
0%
55.44%
Zhejiang Jolly Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
20.33%
EBIT Growth (5y)
41.39%
EBIT to Interest (avg)
40.54
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.05
Sales to Capital Employed (avg)
0.74
Tax Ratio
15.16%
Dividend Payout Ratio
38.04%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.95%
ROE (avg)
12.89%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
2.63
EV to EBIT
13.26
EV to EBITDA
12.13
EV to Capital Employed
2.59
EV to Sales
2.93
PEG Ratio
0.72
Dividend Yield
2.72%
ROCE (Latest)
19.55%
ROE (Latest)
19.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
866.30
897.80
-3.51%
Operating Profit (PBDIT) excl Other Income
218.80
246.40
-11.20%
Interest
4.50
4.10
9.76%
Exceptional Items
0.00
0.00
Consolidate Net Profit
177.30
202.00
-12.23%
Operating Profit Margin (Excl OI)
219.40%
242.50%
-2.31%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is -3.51% vs 17.96% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is -12.23% vs 62.51% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,018.20
2,548.80
18.42%
Operating Profit (PBDIT) excl Other Income
832.10
665.60
25.02%
Interest
14.60
9.40
55.32%
Exceptional Items
-1.70
0.00
Consolidate Net Profit
642.40
516.00
24.50%
Operating Profit Margin (Excl OI)
247.70%
231.60%
1.61%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 18.42% vs 32.27% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 24.50% vs 32.04% in Dec 2024
About Zhejiang Jolly Pharmaceutical Co., Ltd. 
Zhejiang Jolly Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






